Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers

Bipolar Disorders

Volumn 3, Issue 5, 2001, Pages 259-265

  Post, Robert M ^a,b   Altshuler, Lori L ^c   Frye, Mark A ^c   Suppes, Trisha ^d   Rush, A John ^d   Keck Jr , Paul E ^e   McElroy, Susan L ^e   Denicoff, Kirk D ^a   Leverich, Gabriele S ^a   Kupka, Ralph ^f   Nolen, Willem A ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b Stanley Foundation Bipolar Network   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antidepressants; Bipolar; Bupropion; Controlled trial; Depression; Hypomania; Mania; Sertraline; Switching; Venlafaxine

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CHLORAL HYDRATE; CLONAZEPAM; GABAPENTIN; LAMOTRIGINE; LITHIUM; LORAZEPAM; NEUROLEPTIC AGENT; SERTRALINE; TOPIRAMATE; VALPROIC ACID; VENLAFAXINE;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HUMAN; HYPOMANIA; INSOMNIA; LITHIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MANIA; MANIC DEPRESSIVE PSYCHOSIS; MENTAL HEALTH; METHODOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT;

EID: 0034775032     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-5618.2001.30505.x     Document Type: Article

References (50)

1. Possible role of antidepressants in precipitating mania and hypomania in recurrent depression
2. Switch from depression to mania - A record study over decades between 1920 and 1982
3. Psychopharmacology of the switch process in affective illness
4. Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode
5. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode
6. Rapidly cycling affective disorder. Demographics, diagnosis, family history, and course
7. Long-term stability of polarity distinctions in the affective disorders
8. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression
9. A comparison of fluoxetine and imipramine and placebo in patients with bipolar depressive disorder
10. The induction of mania: A natural history study with controls
11. Lithium carbonate and imipramine in prevention of affective episodes
12. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders
13. Course of the manic-depressive cycle and changes caused by treatment
14. Rapid cycling in manic-depressives induced by tricyclic antidepressants
15. Can antidepressants cause mania and worsen the course of affective illness?
16. Do antidepressants cause mania?
17. Tranylcypromine versus imipramine in anergic bipolar depression
18. A double-blind trial of bupropion versus desipramine for bipolar depression
19. Cyclothymic disorder: Validating criteria for inclusion in the bipolar affective group
20. Differentiation of primary affective illness from situational, symptomatic, and secondary depressions
21. Unwanted effects of long-term treatment
22. Antidepressant-induced mania and cycle acceleration: A controversy revisited
23. Drug-induced switching in bipolar disorder: Epidemiology and therapeutic implications
24. Mania and hypomania during antidepressant pharmacotherapy: Clinical and research implications
25. Prophylactic lithium carbonate with and without imipramine for bipolar I patients: A double blind study
26. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder
27. Bupropion versus desipramine in the treatment of bipolar depression
28. The Stanley Foundation Bipolar Treatment Outcome Network: I. Longitudinal methodology
29. The Stanley Foundation Bipolar Treatment Outcome Network: II. Demographics and illness characteristics of the first 261 patients
30. Sertraline: A new specific serotonin reuptake blocker
31. Venlafaxine: A new dimension in antidepressant pharmacotherapy
32. Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis
33. Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum
34. Bupropion: A review of its mechanism of antidepressant activity
35. Long-term preventive care in depression: The use of bupropion in patients intolerant of other antidepressants
36. Bupropion's prophylactic efficacy in bipolar affective illness
37. Bupropion in the long-term treatment of cyclic mood disorders: Mood stabilizing effects
38. Bupropion as a promising approach to rapid cycling bipolar II patients
39. Life charting of affective disorders
40. Preliminary evidence of the reliability and validity of the prospective life-chart methodology (LCM-p)
41. Validation of the prospective NIMH-Life-Chart Method (NIMH-LCM-p) for longitudinal assessment of bipolar illness
42. A rating scale for mania: Reliability, validity and sensitivity
43. The inventory for depressive symptomatology (IDS): Preliminary findings
44. The Inventory of Depressive Symptomatology (IDS): Psychometric properties
45. The global assessment scale
46. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): The CGI-BP
47. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants
48. Antidepressant-associated mania: A controlled comparison with spontaneous mania
49. An examination of descriptive variables and clinical outcomes in a sample of patients with bipolar disorder
50. Risk of depressive relapse in bipolar patients when antidepressants are discontinued